Mina Nikanjam

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim et al. · Nature Communications · 2020 · 276 citations · Full text

Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme

Mina Nikanjam, Andrew R. Gibbs, C. Anthony Hunt et al. · Journal of Controlled Release · 2007 · 157 citations

Nanomedicine, Neuro-oncology, Synthetic Nano-ldl +11

Synthetic Nano-Low Density Lipoprotein as Targeted Drug Delivery Vehicle for Glioblastoma \nMultiforme

Mina Nikanjam, Eleanor A. Blakely, Kathleen A. Bjornstad et al. · eScholarship (California Digital Library) · 2006 · 115 citations

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

Jason K. Sicklick, Shumei Kato, Ryosuke Okamura et al. · Genome Medicine · 2021 · 83 citations · Full text

ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways

Thuc Le, Soumya Poddar, Joseph Capri et al. · Nature Communications · 2017 · 70 citations · Full text

Hematological Malignancy, Cell Regulation, Oncogenic Agent +15